Siemens AG has signed an agreement to acquire Dotmatics, a provider of Life Sciences R&D software based in Boston, for $5.1 billion from Insight Partners.

This acquisition will expand Siemens’ comprehensive Digital Twin technology and AI-powered software into a rapidly growing complementary market. Dotmatics offers a leading platform with a profitable portfolio of scientific applications and multi-modal data management for Life Sciences R&D. The company’s offering accelerates customers’ innovation, delivering next-generation collaboration and contextualized data to enable AI-powered multi-modal drug development.

“By acquiring Dotmatics, we’re strategically strengthening our position in Life Sciences and creating a world-leading AI-powered PLM software portfolio as part of Siemens Xcelerator. Artificial Intelligence has emerged as a transformative force across various industries, and its application in Life Sciences is becoming increasingly important,” said Roland Busch, President and CEO of Siemens AG. “The Dotmatics acquisition is part of our ONE Tech Company growth program, enhancing our leading position in industrial software and helping our customers to innovate even faster.”

“We are thrilled to announce our new chapter with Siemens,” said Thomas Swalla, CEO of Dotmatics. “Combining our next-generation scientific intelligence platform and industry-leading scientific applications together with Siemens’ Digital Twin and AI capabilities, we’ll drive a new wave of innovation in life sciences R&D. Together, we’ll accelerate innovation cycles for our customers and help scientists make breakthrough discoveries faster than ever before shaping the future of scientific innovation.”

Siemens’ expansion within Life Sciences aligns with its strategic goal to accelerate customer innovation across the top industries with the highest R&D spend. The acquisition of Dotmatics enables Siemens to scale its technologies into Life Sciences and to fully address growth opportunities in this market. It will allow Siemens to combine its comprehensive manufacturing expertise, industrial simulation and AI capabilities with Dotmatics’ complementary applications, creating an end-to-end digital thread that connects data from research through to production in Life Sciences.

Closing of the transaction is anticipated for the first half of fiscal year 2026 subject to customary closing conditions and applicable regulatory approvals.

More Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.